From Discovery To Development To Delivery
AZBio is committed to building a top-tier life science industry in Arizona.
Arizona’s bioscience industry has grown in recent years and by 2014 state bioscience firms employed just over 24,000 in nearly 1,300 business establishments. Four of the state’s five bioscience subsectors have contributed to its 2 percent overall employment gain since 2012, led by double-digit job growth in medical devices (up 11 percent). State academic institutions accounted for nearly $400 million in bioscience-related R&D expenditures in 2014 and NIH funding to these and other non-academic institutions totaled $150.6 million in 2015. Arizona inventors have had 1,751 patents issued in bioscience-related classes since 2012, primarily in medical and surgical devices but also in drugs and pharmaceuticals, microbiology and genetics, and in biochemistry. The state has seen a strong increase in venture capital invested in bioscience-related companies in recent years. (Get The Facts)
AZBio Members Are Making LIFE Bettter
AZBio Members discover, develop, and deliver life-saving and life-changing innovations.
Get Connected With Arizona's Bioindustry
A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.
Success Stories – Good News from Arizona’s BioIndustry
Virginia Rybski appointed to the AdvaMed Board of Directors. Ms. Rybski serves as Scotsdale, Arizona based Regenesis’ President and Chief Executive Officer.
C-Path founder Raymond L. Woosley, MD, PhD announces retirement plans.
Agreement establishes 1st Biosignatures Center between ASU and Taiwan’s Chang Gung University – partnership will improve patient outcomes and reduce costs.
TGen Drug Development (TD2) and Flagship Biosciences offer combined oncology and pathology services for pharmaceutical and biotech clients.
- MedCity CONVERGE Cancer Conference
- 07/31/2017 - 08/01/2017
- Focusing on the Cure: CAR T Strategies
- Chemical Development of Anticancer Drugs
- Microfluidics and Nanotechnology Tools for Early Diagnosis and Therapy of Cancer
- After Hours Networking with the AZBio Board